XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
STATEMENTS OF STOCKHOLDERS' DEFICIT - 6 months ended Aug. 31, 2018 - USD ($)
Common Stock
Additional Paid-in Capital
Retained Deficit
Total
Balance at Feb. 28, 2018 $ 131,449 $ 120,146,481 $ (120,385,630) $ (107,700)
Balance (in shares) at Feb. 28, 2018 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski M.D., Ph.D. and related parties   242,484   242,484
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.   557,097   557,097
Net loss     (859,248) (859,248)
Balance at Aug. 31, 2018 $ 131,449 $ 120,946,062 $ (121,244,878) $ (167,367)
Balance (in shares) at Aug. 31, 2018 131,448,444